TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sells $343,397.73 in Stock

TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $28.77 on Friday. The stock’s 50 day moving average is $31.45 and its 200 day moving average is $25.28. TG Therapeutics, Inc. has a one year low of $12.84 and a one year high of $36.84. The firm has a market cap of $4.48 billion, a P/E ratio of -287.67 and a beta of 2.24. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same quarter last year, the firm posted $0.73 EPS. The firm’s revenue for the quarter was down 49.4% on a year-over-year basis. As a group, research analysts expect that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. The Goldman Sachs Group upped their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. TD Cowen began coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. HC Wainwright upped their price objective on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.67.

Institutional Trading of TG Therapeutics

A number of institutional investors have recently bought and sold shares of TGTX. NBC Securities Inc. lifted its stake in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares during the period. Ashton Thomas Private Wealth LLC bought a new stake in TG Therapeutics in the second quarter worth approximately $35,000. Blue Trust Inc. lifted its stake in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 849 shares during the period. ORG Wealth Partners LLC bought a new position in shares of TG Therapeutics during the 3rd quarter worth approximately $53,000. Finally, Values First Advisors Inc. acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth approximately $58,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.